<p>Radiotherapy is increasingly relevant in the multidisciplinary treatment of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC). Stereotactic body radiotherapy (SBRT) enables ablative radiation doses under image-guided motion control and is associated with consistently high rates of local control (LC) in unresectable or locally advanced tumors. In HCC, SBRT shows good outcomes in various clinical settings, for example as a definitive therapy in inoperable tumors, with results similar to those of already established locoregional therapies, such as transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). According to comparative studies, SBRT often achieves higher rates of LC, particularly in larger lesions or tumors located in anatomically challenging sites, with largely comparable overall survival (OS) compared with other local treatment modalities. Furthermore, SBRT is successfully used as a bridging therapy or for downstaging prior to liver transplantation, with high rates of pathological tumor response without negative effects on transplant eligibility. SBRT is also increasingly being investigated in combination with systemic therapies, with early data showing encouraging results, particularly in combination with immune checkpoint inhibitors (ICI). In CCC, radiotherapy has gained importance due to the high rates of local recurrence after curatively intended surgery. In the adjuvant setting, radiotherapy is associated with improved survival, particularly in patients with unfavorable pathological features, such as positive resection margins or nodal involvement. In selected cases with locally advanced or anatomically unfavorable tumors, neoadjuvant radiochemotherapy may be beneficial.</p>